Mechanism of Action
Dual GLP-1R / GCGR Agonism
OXM's C-terminal octapeptide extension (KRNRNNIA) enables glucagon receptor binding, while the shared GLP-1 (7-36) core mediates GLP-1R activation. At GLP-1R: reduces food intake (hypothalamic GLP-1R), slows gastric emptying, stimulates glucose-dependent insulin secretion. At GCGR: stimulates hepatic glycogenolysis and gluconeogenesis (raising blood glucose, a concern in diabetes), but also activates thermogenic adipose tissue brown fat pathways and increases hepatic fatty acid oxidation. The net metabolic outcome depends on dose: at the concentrations produced physiologically postprandially, the GLP-1R-mediated satiety dominates; at the concentrations achieved with exogenous research dosing, both axes are pharmacologically active.
Energy Expenditure Enhancement (Glucagon Contribution)
The glucagon receptor component of OXM activates brown adipose tissue thermogenesis via sympathetic nervous system stimulation (GCGR on sympathetic terminals) and upregulates UCP-1 (uncoupling protein-1) in brown fat mitochondria, the heat-generating protein that uncouples ATP synthesis from oxygen consumption. This thermogenic effect increases resting energy expenditure by 10-15% in rodent models - a contribution not present with GLP-1 agonism alone. The weight loss from OXM exceeds that from equimolar GLP-1 agonism in both animal and human studies, and the additional loss is attributable to this energy expenditure increase.
Research Summary
Obesity and Weight Loss Trials
Phase II/III ClinicalWynne et al (2005, NEJM-adjacent, published in Endocrinology) showed subcutaneous OXM three times daily before meals for 4 weeks reduced caloric intake by 25% and achieved 2.3 kg weight loss versus 0.5 kg placebo in a crossover study. Importantly, resting energy expenditure increased by 3.5% in the OXM group, consistent with the thermogenic glucagon component. A Phase II dose-ranging study confirmed weight loss of 3-4 kg at 4 weeks with the highest dose (400-800 nmol SC pre-meal), exceeding what was achievable with GLP-1 agonists alone at that time.
Proof of Concept for Retatrutide / Multi-Agonists
Strong EvidenceOXM's clinical data provided the pharmacological rationale for developing synthetic dual and triple agonists. Retatrutide (GIP/GLP-1/glucagon triple agonist) in Phase III trials has shown 24% average body weight reduction, the highest of any approved or late-stage drug. The glucagon component's thermogenic contribution is now understood to account for approximately 5-8% additional weight loss beyond what GLP-1 alone achieves. OXM is thus the natural molecule whose mechanism validated the entire multi-agonist drug development strategy.
Calculate your Oxyntomodulin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Weight management research | 400-800 nmol SC | Three times daily, 30 min before meals | Subcutaneous |
| Metabolic / energy expenditure | 400 nmol SC | Twice to three times daily | Subcutaneous |
OXM requires 3x daily dosing due to its short half-life (10-12 min), making it practical mainly for controlled research settings. For practical weight management applications, the next-generation synthetic analogs (dual GLP-1/glucagon agonists, retatrutide) with extended half-lives are more suitable. OXM's glucagon receptor activity raises blood glucose, monitor glucose carefully, especially if combining with insulin. The glucagon agonism can partially offset GLP-1-mediated insulin secretion, complicating glycemic management in diabetics.
Interactions
Safety Profile
OXM Phase II human trials show a tolerability profile similar to GLP-1 agonists: nausea and reduced appetite are the primary effects (both therapeutically desirable at research doses). The glucagon receptor activity raises blood glucose transiently, in healthy non-diabetic subjects this is offset by GLP-1R-mediated insulin secretion, but in diabetics or insulin users this requires careful monitoring. No significant cardiovascular adverse effects were identified in Phase II studies. The short half-life means adverse effects resolve quickly if dosing is stopped. Long-term safety data is not available given the lack of late-stage clinical development (pharmaceutical interest having moved to longer-acting synthetic analogs). Not WADA prohibited. Not FDA approved. Not scheduled.
References
- [1]Wynne K et al. "Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial." Diabetes. 2005;54(8):2390-2395.
- [2]Baggio LL, Drucker DJ. "Oxyntomodulin: a novel link between gastric acid and metabolism." Gastroenterology. 2004;127(3):994-996.
- [3]Jepsen SL et al. "Synergistic effects of glucagon and GLP-1 on the postprandial period." Nat Commun. 2023;14(1):3060.